Valuation: Control Bionics Limited

Market Cap 30.49M 21.7M 18.62M 17.38M 15.95M 29.99M 2.07B 205M 80.32M 1.04B 81.49M 79.71M 3.44B P/E 2024
-1.4x
P/E 2025 -1.3x
Enterprise Value 30.25M 21.53M 18.47M 17.25M 15.82M 29.76M 2.06B 204M 79.69M 1.03B 80.85M 79.09M 3.41B EV / Sales 2024
1.92x
EV / Sales 2025 1.4x
Free-Float
73.48%
Yield 2024 *
-
Yield 2025 -
1 day-3.23%
1 week-3.23%
Current month-6.25%
1 month-13.04%
3 months-1.64%
6 months+7.14%
Current year-1.64%
1 week 0.06
Extreme 0.056
0.06
1 month 0.06
Extreme 0.056
0.07
Current year 0.05
Extreme 0.05
0.1
1 year 0.03
Extreme 0.032
0.1
3 years 0.03
Extreme 0.026
0.1
5 years 0.03
Extreme 0.026
0.73
10 years 0.03
Extreme 0.026
1.24
Manager TitleAgeSince
Chief Executive Officer - 2023-01-18
Director of Finance/CFO - 2024-05-12
Chief Tech/Sci/R&D Officer - 2013-12-31
Director TitleAgeSince
Chairman - 2025-11-30
Chairman 66 2025-11-18
Director/Board Member - 2023-01-18
Change 5-day change 1-year change 3-year change Capi.($)
-3.23%-3.23%+57.89%-29.41% 19.59M
+2.53%-1.51%+20.76%-33.74% 16.5B
-6.49%-8.51%-31.78%+89.39% 1.72B
+0.60%-3.80%-26.03%+25.41% 966M
+2.76%-6.95%-48.40%-81.98% 921M
0.00%+0.05%+63.80%-6.58% 778M
-2.10%-1.76%-40.65%-49.41% 680M
-4.14%-1.27%-43.17%-42.07% 613M
+0.69%+7.40%-39.63%-35.58% 444M
+1.59%+2.20%+65.16%+43.82% 417M
Average -0.82%-2.94%-2.21%-12.02% 2.31B
Weighted average by Cap. +1.28%-4.15%+9.73%-22.41%

Financials

2024 2025
Net sales 5.35M 3.81M 3.27M 3.05M 2.8M 5.26M 364M 36M 14.1M 183M 14.3M 13.99M 604M 6.14M 4.37M 3.75M 3.5M 3.21M 6.05M 418M 41.35M 16.19M 210M 16.43M 16.07M 693M
Net income -5.91M -4.21M -3.61M -3.37M -3.09M -5.82M -402M -39.79M -15.58M -202M -15.81M -15.46M -667M -6.11M -4.35M -3.73M -3.48M -3.2M -6.01M -416M -41.1M -16.09M -208M -16.33M -15.97M -689M
Net Debt -96.95K -69.02K -59.2K -55.28K -50.72K -95.38K -6.6M -652K -255K -3.31M -259K -254K -10.94M -237K -169K -145K -135K -124K -233K -16.14M -1.6M -625K -8.1M -634K -620K -26.77M
Logo Control Bionics Limited
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Its products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography output. This output is then sent wirelessly via NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse and the NeuroNode acts like a mouse button. It is commercializing its advancement in its technology, NeuroStrip. It is focused on neuromuscular rehabilitation and athletic optimization.
Employees
-
Date Price Change Volume
26-08-19 A$0.0600 -3.23% 1,166,821
26-08-18 A$0.0620 +10.71% 798,893
26-08-17 A$0.0560 -5.08% 2,636,760
26-08-14 A$0.0590 -1.67% 832,900
26-08-13 A$0.0600 -3.23% 4,187,042

Annual profits - Rate of surprise